

JAST (Journal of Animal Science and Technology) TITLE PAGE

Upload this completed form to website with submission

ARTICLE INFORMATION	Fill in information in each box below
Article Type	Research article
Article Title (within 20 words without abbreviations)	A comprehensive assessment of immunomodulatory potentials of Korean antler velvet extract in mouse and neurodegenerative <i>Caenorhabditis elegans</i> models
Running Title (within 10 words)	Exploring immunomodulatory potential of Korean antler velvet extracts
Author	Anna Kang ¹ , Junbeom Lee ¹ , Ju Young Eor ¹ , Min-Jin Kwak ¹ , Yong-An Kim ² , Sangnam Oh ³ , Younghoon Kim ^{1*}
Affiliation	1 Department of Agricultural Biotechnology and Research Institute of Agriculture and Life Science, Seoul National University, Seoul 08826, Korea 2 Korea RND Nonghyup, Seoul 04949, Korea 3 Department of Functional Food and Biotechnology, Jeonju University, Jeonju 55069 Korea
ORCID (for more information, please visit https://orcid.org)	Anna Kang (https://orcid.org/0000-0003-0208-6234) Junbeom Lee (https://orcid.org/0000-0001-6502-1556) Ju Young Eor (https://orcid.org/0000-0002-3764-3339) Min-Jin Kwak (https://orcid.org/0000-0001-9832-3251) Sangnam Oh (https://orcid.org/0000-0002-2428-412x) Younghoon Kim (https://orcid.org/0000-0001-6769-0657)
Competing Interests	No potential conflict of interest relevant to this article was reported.
Funding Sources State funding sources (grants, funding sources, equipment, and supplies). Include name and number of grant if available.	National Agricultural Cooperative Federation (NACF) Agricultural and livestock products safe distribution and consumption technology development program (Project No. 320111-1) Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) (NRF-2018R1D1A3B07050304)
Acknowledgments	This study received support through grants from the National Agricultural Cooperative Federation (NACF) and the Agricultural and Livestock Products Safe Distribution and Consumption Technology Development Program (Project No. 320111-1), Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, and Forestry (IPET). Additionally, funding was provided by the National Research Foundation of Korea Grant, supported by the Korean government (NRF-2018R1D1A3B07050304).
Availability Of Data And Material	Upon reasonable request, the datasets for this study can be obtained from the corresponding author.
Authors' Contributions Please specify the authors' role using this form.	Conceptualization: Kim YA, Oh S, Kim Y Data curation: Eor JY, Kwak MJ, Oh S, Kim Y Formal analysis: Kang A, Lee J Methodology: Kang A, Lee J, Eor JY, Kwak MJ, Kim Y Software: Lee J, Eor JY, Kwak MJ, Kim Y Validation: Kang A, Lee J, Oh S, Kim Y Investigation: Kang A, Lee J Writing-original draft: Kang A, Lee J Writing-review & editing: Eor JY, Kwak MJ, Kim YA, Oh S, Kim Y
Ethics Approval And Consent To Participate	This animal experiment was conducted with the approval of the Institutional Animal Care and Use Committee (IACUC) at Seoul National University (SNU-221025-1).

CORRESPONDING AUTHOR CONTACT INFORMATION

For the corresponding author (responsible for correspondence, proofreading, and reprints)	Fill in information in each box below
First name, middle initial, last name	Younghoon Kim
Email address—this is where your proofs will be sent	ykeys2584@snu.ac.kr
Secondary Email address	
Address	Department of Agricultural Biotechnology and Research Institute of Agriculture and Life Science, Seoul National University, Seoul 08826, Korea
Cell phone number	+82-02-880-4808
Office phone number	+82-02-880-4808
Fax number	+82-02-873-2271

ACCEPTED

1 **Running head:** Exploring immunomodulatory potential of Korean antler velvet extracts
2

3
4 **A comprehensive assessment of immunomodulatory potentials of Korean**
5 **antler velvet extract in mouse and neurodegenerative *Caenorhabditis elegans***
6 **models**

7
8 Anna Kang¹, Junbeom Lee¹, Ju Young Eor¹, Min-Jin Kwak¹, Yong-An Kim², Sangnam Oh^{3*}, and
9 Younghoon Kim^{1*}

10
11 ¹*Department of Agricultural Biotechnology and Research Institute of Agriculture and Life Science, Seoul*
12 *National University, Seoul 08826, Korea*

13 ²*Korea RND Nonghyup, Seoul 04949, Korea*

14 ³*Department of Functional Food and Biotechnology, Jeonju University, Jeonju 55069, Korea*

15
16
17
18
19
20
21 *To whom correspondence should be addressed: osangnam@jj.ac.kr and ykeys2584@snu.ac.kr

22
23

Abstract

This study conducts a comprehensive analysis of deer antler velvet's impact, with a specific emphasis on mouse models and *in vitro* experiments. The study navigates the intricacies of antler velvet's variability, encompassing considerations of drying methods, extraction techniques, and anatomical regions of antlers. Employing a diverse array of processing methods, this study prioritizes both food safety and the consistent intake of deer antler velvet extracts. The study scrupulously evaluates toxicity and immune-boosting properties through exhaustive assessments, utilizing *Caenorhabditis elegans*, immunosuppressive mouse models, and immune cells. The study unfolds the repercussions of deer antler velvet extract on the lifespan, neuromuscular functions, and cognitive abilities of *C. elegans*. Additionally, this study explores the extract's potential to alleviate toxicity induced by cyclophosphamide (CPA) in a mouse model, with a focus on inflammation, metabolic disorders, and gut microbiota composition. The antler velvet extract prevents immune dysregulation caused by CPA treatment by ameliorating systemic inflammation and restoring energy metabolism. Furthermore, antler velvet extract treatment significantly transforms the gut microbiota of an immunosuppressive mouse model by fostering the proliferation of commensal bacteria such as *Lactobacillus*, *Akkermansia*, and *Lachnospiraceae* at the genus level. Moreover, antler velvet treatment enhances the activity of natural killer cells against YAC-1 lymphoma while tempering overactivity among immune cells to baseline levels. In conclusion, this study provides nuanced insights into the diverse benefits of antler velvet extract, encouraging sustained research to unveil its complete potential in the realms of mouse models and *in vitro* experiments.

Keywords: Antler velvet, Fresh antler velvet extracts, Biotherapeutic agents, Immune regulation, animal models

47 **Introduction**

48

49 Deer antler velvet, sourced from the antlers of deer (*Cervus canadensis* Erxleben), has a fascinating
50 historical backdrop dating back to 168 B.C., as evidenced by tomb scrolls from the Han Dynasty in Nanyang,
51 China. Deer antler velvet's roots run deep in traditional East Asian medicine, with the Shen Nong Ben Cao
52 Jing documenting its use for diverse ailments since before 2000 B.C. [1, 2]. Recognized by the United
53 States Food and Drug Administration (FDA), deer antler velvet comes in various forms—powder, extracts,
54 and spray products. The FDA approval has paved the way for numerous deer antler velvet spray products
55 for external use and dietary supplements, addressing needs such as enhancing sports performance and aiding
56 injury recovery [3, 4]. Recent research has focused on understanding the chemical composition,
57 physiologically active compounds, functional lipids, and pharmacological aspects of deer antler velvet,
58 hinting at its potential applications in health and medical therapeutics [5, 6].

59 Delving into the pharmacological attributes of antler velvet has been enlightening, uncovering a rich
60 array of physiologically active elements, including growth factors, hormones, minerals, and proteins. This
61 composition suggests a range of potential physiological impacts, with research primarily focusing on anti-
62 inflammatory, antioxidant, promotion of skeletal development, immune enhancement, and energy-boosting
63 effects [5, 7-9]. Ongoing studies are now seeking to discern the potential positive effects of antler velvet on
64 blood circulation, vasodilation, and blood pressure regulation. While these findings hold promise,
65 additional research and clinical trials are crucial for more conclusive insights into the multifaceted effects
66 of antler velvet [10, 11].

67 However, the effectiveness of deer antler velvet may fluctuate based on drying methods (heat-drying,
68 air-drying, and freeze-drying) [12, 13], extraction techniques (alcohol extraction, supercritical extraction,
69 and aqueous extraction) [8, 14, 15], and anatomical regions of antlers (tip, upper (U), middle (M), and base
70 (B)) [16, 17]. This variability poses challenges for standardization, raising concerns about the potential
71 degradation or molecular breakdown of functional substances.

72 Consequently, this study undertook the intricate task of employing a myriad of processing methods for
73 deer velvet antler, ensuring the utmost standards in both food safety and the stable intake of extracts
74 obtained. Simultaneously, this study assessed the toxicity and immune-boosting properties inherent in deer
75 antler velvet through a comprehensive array of evaluations. This specific experimental endeavor
76 encompassed a diverse array of deer antler velvet extracts. These included fresh antler velvet extracts (FAV),
77 fermented freeze-dried antler velvet extracts (FFA), dried antler velvet extracts (DVA), and naturally shed
78 antler extracts from an aged deer (CFA). Following this generous provision, each antler velvet sample
79 underwent meticulous segmentation into U, M, and B components for further detailed analysis. We used a
80 strategic combination of *Caenorhabditis elegans*, immunosuppressive mouse models, and immune cells for
81 a thorough examination of toxicity aspects.

82 The prominence of *C. elegans* in toxicity studies have been underscored by its not only sharing significant
83 genomic similarities with humans but also exhibiting unmistakable age-dependent metabolic changes and
84 a comparatively abbreviated life span, rendering it a model of choice for expedited toxicity assessments
85 [18-20].

86 In the evaluation of the immune-boosting properties of antler velvet, we navigate the complexities by
87 incorporating a cyclophosphamide (CPA)-induced immunosuppressive mouse model [21, 22]. This model
88 has been characterized by heightened tumor cell-centric inflammation and a proclivity for immunogenic
89 cell death. Simultaneously, we engaged in co-cultures featuring tumor YAC-1 cells with antler velvet-
90 treated natural killer cells, revealing a compelling enhancement in the sensitivity of natural killer cells
91 toward tumor cells [23, 24]. This multifaceted approach not only ensured a comprehensive understanding
92 but also opens avenues for nuanced insights into both the safety and the potential immune-enhancing effects
93 encapsulated within deer antler velvet.

94

95

96 **Materials and methods**

97

98 **Antler velvet sample preparation**

99 To standardize the functionality and advance the development of applications for deer antler velvet
100 products, diverse processing methods were applied. Prior to the processing stages, meticulous disease
101 testing was conducted on samples sourced from the Korea RND Nonghyup (Seoul, Korea). Collaborative
102 analyses, in partnership with Yonsei University (Seoul, Republic of Korea) and the Chungbuk Institute of
103 Health and Environment (Chungcheongbuk-do, Republic of Korea), were conducted to assess deer
104 tuberculosis *via* PCR, *Brucella* through PCR, and chronic wasting disease in deer. All samples exhibited
105 negative results for these three diseases (data not shown).

106 For this particular experiment, Korea RND Nonghyup generously provided FAV, FFA, DAV, and CFA.
107 Subsequently, each antler velvet sample was segmented into U, M, and B components. Prior to their
108 utilization in the experiment, the samples underwent dissolution in distilled water and filtration.

109

110 ***C. elegans* analysis**

111 1) *C. elegans* growth condition

112 The *C. elegans* strain CF512 (*fer-15(b26)II*; *fem-1(hc17)IV*) and strain CL4176 (*dvIs27 [myo-3p::A-*
113 *Beta (1-42)::let-851 3'UTR) + rol-6(su1006)] X.*) were acquired from the Caenorhabditis Genetic Center
114 (St. Paul, MN, USA) and sustained on nematode growth medium (NGM) plates at a controlled temperature
115 of 15°C. The conventional nutritional substrate for *C. elegans*, *Escherichia coli* strain OP50 (OP50),
116 underwent cultivation in Luria–Bertani medium (Miller; BD Difco, Franklin Lakes, NJ, USA) at 37°C for
117 a duration of 24 h with continuous agitation at 225 rpm. As a component of the positive control diet for *C.*
118 *elegans*, *Lactocaseibacillus rhamnosus* GG (LGG) was employed, and LGG was cultured on BD Difco's
119 de Man, Rogosa & Sharpe (Franklin Lakes, NJ, USA) at 37°C for a period of 24 h. To ensure extended

120 preservation, bacterial cultures were stored at -80°C , supplemented with 15% glycerol as a cryoprotectant.
121 Prior to the start of experimental analyses, OP50 underwent two sequential subculturing procedures.
122

123 2) Lifespan assay

124 For the lifespan assay, eggs were extracted from egg-bearing worms using a sodium hypochlorite–
125 sodium hydroxide solution (Sigma-Aldrich) and synchronized to L1 stage worms on NGM plates at 25°C .
126 The young adult L4 staged worms were then transferred to 35-mm-diameter NGM plates seeded with OP50
127 and the antler velvet extracts ($100\ \mu\text{g}/\text{mL}$). Throughout the experiment, all worms were daily transferred to
128 fresh OP50 lawns until the termination of the entire cohort.
129

130 3) Thrashing assay

131 To evaluate the motor ability of *C. elegans*, the number of thrashes in the M9 buffer was recorded. After
132 exposing worms to antler velvet extracts ($100\ \mu\text{g}/\text{mL}$) and OP50 for 10 days ($n=10$ per group, three
133 replicates), they were transferred to a sterile 35-mm-diameter NGM agar plate without bacteria. The worms
134 were allowed to crawl for a minute to remove aggregated bacteria. Subsequently, another sterile 35-mm-
135 diameter NGM agar plate filled with 1 mL of M9 buffer was prepared. A single worm was introduced into
136 the buffer and allowed to acclimate to the environment. The number of thrashes was then counted for 30 s,
137 with a valid movement defined as the worm bending its head and tail to the same side.
138

139 4) Neuromuscular ability assay

140 To evaluate the neuromuscular ability of *C. elegans*, the number of pharyngeal pumps was recorded.
141 After exposing worms to antler velvet extracts ($100\ \mu\text{g}/\text{mL}$) and OP50 for 10 days ($n = 10$ per group, three
142 replicates), they were transferred to a sterile 35-mm-diameter NGM agar plate without bacteria. The worms
143 were allowed to crawl for a minute to remove aggregated bacteria. Subsequently, another sterile 35-mm-
144 diameter NGM agar plate filled with 1 mL of M9 buffer was prepared. A single worm was introduced into

145 the buffer and allowed to acclimate to the environment. The number of pharyngeal pumps was then counted
146 for 30 s under a microscope, with a valid movement defined as rhythmic contractions of the pharynx.

147

148 5) Chemotaxis assay

149 The chemotactic ability of *C. elegans* serves as a proxy for olfactory behavior. To assess olfactory
150 plasticity, the responsiveness of worms to attractant and repellent chemicals was measured. After exposing
151 worms to antler velvet extracts (100 µg/mL) and OP50 for 10 days (n = 10 per group, three replicates), they
152 were transferred to a sterile 35-mm-diameter NGM plate without bacteria, allowing them to crawl for 1 min
153 to remove aggregated bacteria. Subsequently, another sterile 35-mm-diameter NGM agar plate was
154 prepared with a drop of 100 mM isopropyl alcohol diluted in 100% EtOH (Merk, Kenilworth, NJ, USA) as
155 an attractant, dried on the edge of the plate. Worms were then placed in the middle of the plate and allowed
156 to freely crawl for 30 min, and the number and direction of turns toward the attractant were recorded. The
157 same procedure was repeated using the repellent, 30% octanol (v/v) in 100% EtOH.

158

159 ***In vivo* mouse experimental scheme**

160 1) Establishment of an immune-suppressive mouse model

161 Overall, 20 male C57BL/6 mice, aged 10 weeks, were purchased from SamTako Bio (Korea).
162 Subsequently, the mice were grouped into five individuals per cage and housed under controlled conditions
163 at 23°C ± 1°C with 55% ± 5% humidity, following a 12-hour light/dark cycle. Mice were provided with *ad*
164 *libitum* access to sterile water and a standard chow diet. A 1-week acclimatization period with the normal
165 diet preceded the commencement of the experimental procedures. Following initial weighing, the mice
166 were randomly allocated into five groups (n = 4 for each group): CONT (vehicle control group),
167 administered orally with PBS (200 µL/day); CPA (negative control group), administered orally with PBS
168 (200 µL/day) and intraperitoneal injection of CPA solution (100 mg/kg/day); CPA + β-glucan (positive
169 control group), administered orally with β-glucan (250 mg/kg/day) and intraperitoneal injection of CPA

170 solution (100 mg/kg/day); CPA + F100 (low concentration treatment group), administered orally with FAV
171 upper extract (100 mg/kg/day) and intraperitoneal injection of CPA solution (100 mg/kg/day); and CPA +
172 F300 (high concentration treatment group), administered orally with FAV upper extract (300 mg/kg/day)
173 and intraperitoneal injection of CPA solution (100 mg/kg/day).

174 Throughout the experiment, all groups received oral administration for a duration of 28 days, with the
175 CPA, CPA + F100, and CPA + F300 groups additionally receiving intraperitoneal injections of CPA from
176 days 22 to 28. Over the course of the 28-day period, food intake, water intake, and body weight were
177 recorded weekly. The entire set of animal experimental procedures adhered to the protocols and received
178 approval from the Institutional Animal Care and Use Committee of Seoul National University, as indicated
179 by certificate SNU-221025-1.

180

181 2) Serum analysis

182 Blood samples were obtained from the postcaval vein of mice and centrifuged at $1,500 \times g$ for 15 min to
183 obtain serum, which was subsequently stored at -80°C for further analysis. The levels of aspartate
184 transaminase (AST/GOT), alanine transaminase (ALT/GPT), gamma-glutamyl transpeptidase (GGT), total
185 cholesterol, and glucose were determined using Embiel GOT, GPT, GGT, Total Cholesterol, and Glucose
186 test kits (Embiel Ltd., Korea) to assess the extent of inflammation in the mice.

187

188 3) Metagenomic analysis

189 Fecal samples were systematically collected from each experimental cohort on the day of sacrifice.
190 Genomic DNA (gDNA) was meticulously extracted utilizing the DNeasy PowerSoil Pro Kit (Qiagen,
191 Hilden, Germany). Subsequently, the V4 region of the 16S rRNA genes was selectively amplified with the
192 V4 amplicon primer set (forward: 515F, 5'-
193 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTGCCAGCMGCCGCGGTAA-3'; reverse:
194 806R, 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGACTACHVGGGTWTCTAAT-3').

195 Illumina® MiSeq sequencing was conducted to acquire high-throughput data. The subsequent
196 bioinformatic analysis of the MiSeq paired-end sequencing data was conducted utilizing Mothur software
197 (v. 1.44.3). Evaluation of bacterial alpha diversity, quantified by Shannon and Chao indices, involved a
198 nonparametric one-way analysis of difference ($p < 0.05$), the Kruskal–Wallis test, and Tukey’s post hoc
199 analysis. Welch’s t-test was employed to discern differences in the relative abundance of bacterial taxa.
200 The weighted and unweighted UniFrac metrics, calculated based on the operational taxonomic unit table
201 and the phylogenetic tree, facilitated an assessment of bacterial beta diversity. Visualization of the results
202 occurred through principal coordinate analysis (PCoA) plots, portraying distinctive clustering patterns
203 within the fecal microbiome of each experimental group.

204

205 **Cell culture and cytotoxicity assay**

206 The YAC-1 lymphoma cell line obtained from mice, the Raw264.7 macrophage cell line from mice, and
207 the NK92MI natural killer cell (NK cell) line employed in this study were sourced from the American Type
208 Culture Collection (Manassas, VA, USA). All cellular entities were cultured in Roswell Park Memorial
209 Institute 1640 medium (Gibco, Grand Island, NY, USA), supplemented with 10% heat-inactivated fetal
210 bovine serum (Gibco), 100 U/mL penicillin, and 100 µg/mL streptomycin (Gibco), within a controlled
211 environment at 37°C with 5% CO₂ in a humidified incubator.

212 For assays involving NK cells, YAC-1 and Raw264.7 target cells were individually cultured and seeded
213 in 96-well cell culture plates, with YAC-1 cells at a density of 3.0×10^6 cells/mL and Raw264.7 cells at 1.5
214 $\times 10^5$ cells/mL. Once reaching full confluency, NK cells were introduced to the target cells for cocultivation
215 at a ratio of 50:1 (target:NK cell). Prior to the coculture, NK cells were treated with FAV upper extract (100
216 µg/mL) 24 h prior. Following a 4-hour incubation in a controlled environment at 37°C with 5% CO₂, the
217 medium was harvested and subjected to the LDH cytotoxicity assay (Abcam, Cambridge, UK) according
218 to the manufacturer’s protocol.

219

220 **Statistical analysis**

221 In the present study, all data points underwent analysis and are presented as the mean \pm standard deviation.
222 To discern significant differences, statistical tests, including the Student's t-test, one-way ANOVA, and
223 two-way ANOVA, were conducted utilizing GraphPad Prism 9.5.0 (GraphPad Software). The significance
224 level for the statistical analyses was predetermined at p values of <0.05 (*), <0.01 (**), <0.001 (***), and
225 <0.0001 (****).

227 **Results and discussion**

229 **Antler velvet extract increases the lifespan of *C. elegans***

230 *C. elegans*, an extensively utilized genetic model organism capable of mimicking numerous human
231 diseases, holds considerable value for *in vivo* studies at both metabolic and genetic levels [25, 26]. This
232 study employed the *C. elegans* lifespan assay to scrutinize the toxicity of distinct antler velvet extracts,
233 including FAV, FFA, DAV, and CFA. Initially, we explored the differential effects of various regions
234 within FAV, specifically the upper (FAVU), middle (FAVM), and base (FAVB). Intriguingly, FAVU
235 exhibited the most significant increase in *C. elegans* lifespan, reaching 21.4% compared with OP50
236 treatment, followed by FAVM with a 14.3% increase and FAVB with a 7.1% increase (Fig. 1A–C).
237 Consequently, we opted to proceed with further experiments focusing on the upper regions of antler velvet.

238 Subsequently, the study investigated distinct effects associated with various processing methods of antler
239 velvet by exposing *C. elegans* to extracts from the upper region of FAV, FFA, DAV, and CFA. The results
240 indicated that FAVU showed the most significant enhancement in lifespan relative to other methods (Fig.
241 1A), FFAU displaying the next highest increment at 14.3%, succeeded by DAVU with a 7.1% increase,
242 while CFAU did not present a notable difference in comparison to OP50 (Fig. 1A, D–F). While variations
243 were observed based on the region and processing methods, the overarching outcome highlighted the host-
244 beneficial nature of all antler velvet extracts, with no detectable toxicity.

245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269

Antler velvet extract increases the neuromuscular and cognitive functions of *C. elegans*

Furthermore, considering that antler velvet extraction may encompass preventative measures against cognitive impairment and exhibit antiaging effects, this study delves into assessing the neuromuscular and cognitive functions of *C. elegans*, which are closely associated with metabolic deterioration due to aging [27-29]. The thrashing assay, a valuable tool for identifying motor neuron defects, measured the thrashing frequency of *C. elegans* in a liquid state. Notably, among treatments with upper antler velvet extracts, FAVU and DAVU significantly mitigated the age-related decline in thrashing, showing improvements of $13.7\% \pm 8.0\%$ and $41.5\% \pm 4.6\%$, respectively (Fig. 1G). Subsequently, the rhythmic pharyngeal pumping of *C. elegans*, integral to various physiological and behavioral aspects such as circulation and locomotion, was examined [30, 31]. These rhythmic activities, categorized as myogenic or neurogenic, showed a general increase in pumping rates among the aged *C. elegans* treated with upper antler velvet extracts, notably with FAVU exhibiting a $17.0\% \pm 4.4\%$ increase, DAVU with $6.9\% \pm 5.1\%$, and CFAU with $8.9\% \pm 4.0\%$ (Fig. 1H). The study further explored the potential direct benefits of upper antler velvet extracts on host cognitive function through a chemotactic assessment of *C. elegans*. The chemotaxis assay, examining responses to attractants and repellents, proved instrumental in analyzing the functionality of the chemical sensory system or neurons. Enhanced cognitive function and improved brain health assessments were evident in *C. elegans* treated with FAVU and DAVU, surpassing the OP50 control groups (Fig. 1I, J). In the course of this study, our focus has been on systematically evaluating the holistic toxicity of antler velvet extracts subjected to diverse processing methods on living organisms. Upon a comprehensive analysis of the collective findings in the model organism *C. elegans*, a diverse range of favorable outcomes associated with antler velvet extracts became apparent. Notably, these extracts manifested a positive impact on the host by augmenting lifespan and ameliorating motor and cognitive functions affected by the aging process. Consequently, our attention shifted toward elucidating the intricate mechanisms underlying the immunoregulatory effects of antler velvet extracts, utilizing a transgenic *C. elegans* model for in-depth exploration.

270

271 **Antler velvet extract increases the motor functionality of neurodegenerative transgenic worms**

272 Expanding on the upper results, we sought to delve deeper into the anti-inflammatory effects of antler
273 velvet extracts, particularly focusing on FAVU, which demonstrated favorable impacts across various
274 parameters. This study aimed to scrutinize the activation status of key gene groups critically involved in *C.*
275 *elegans*, especially those associated with neurodegenerative brain diseases. The transgenic worm CL4176,
276 specifically engineered to accumulate β -amyloid peptide, an essential marker of Alzheimer's disease
277 pathology, was instrumental in this study. Intriguingly, on day 0, no behavioral disparities were noted
278 between the OP50-treated group and FAVU. However, after 5 days of exposure, a significant mitigation of
279 muscular degeneration caused by β -amyloid peptide was observed in terms of thrashing and pharyngeal
280 pumping. Although the chemotaxis assay did not yield significant results, a conspicuous trend indicated
281 that FAVU could protect the cognitive abilities of *C. elegans*, enabling them to recognize attractants and
282 repellents (Fig. 1K–N). This underscores the protective attributes inherent in upper antler velvet extracts,
283 extending beyond safeguarding motor neurons to mitigating impairments in neuromuscular function,
284 sensory neurons, and cognitive capabilities. These alterations suggest that the administration of antler velvet
285 holds promise in alleviating symptoms induced by disease, particularly by modulating the hyperimmune
286 response triggered by the accumulation of β -amyloid peptide in *C. elegans*. In a parallel context, seeking a
287 more profound understanding of the immunoregulatory impact of antler velvet extracts on vertebrate
288 animals, we conducted experiments employing immunosuppressed mice.

289

290 **Antler velvet extract mitigates the toxicity induced by CPA in the mouse model**

291 CPA, a widely used chemotherapy and immunosuppressive agent, serves as an alkylating agent to
292 suppress rejection reactions in organ and bone marrow transplants and for treating malignant tumors.
293 However, owing to CPA's nonselective toxicity, it can impact normal cells, resulting in side effects such
294 as anemia, alopecia, and thrombocytopenia. The potential long-term use-associated concerns prompted an

295 investigation into whether antler velvet's upper region could mitigate CPA-induced toxicity in mice. The
296 experimental design is shown in Fig. 2A. Notably, CPA treatment led to a significant decrease in body
297 weight gain. By the end of the experiment, the CPA group exhibited a body weight reduction of $11.8\% \pm$
298 2.0% compared with the normal (CONT) group. Conversely, the FAVU low and high treatment groups
299 demonstrated a recovery in body weight of $2.93\% \pm 0.75\%$ and $2.89\% \pm 0.46\%$, respectively (Fig. 2B).
300 Daily feed and water intake were also significantly reduced in the CPA treatment group, with no notable
301 differences observed between groups (Fig. 2C).

302 Previous research suggests that a compromised immune system may render individuals more susceptible
303 to infections or inflammatory conditions affecting the colon. Inflammatory responses within the colon can
304 lead to alterations in tissue structure, potentially resulting in a reduction in colon length [32-34].
305 Additionally, the correlation between immune decline and spleen weight is often associated with the
306 spleen's role in the immune system. Diminished immune activity can influence the spleen's response,
307 potentially causing changes in its size or weight. The spleen is integral to filtering blood, eliminating
308 damaged blood cells, and participating in immune responses by generating white blood cells and antibodies.
309 Variations in immune function may impact the demand on the spleen, influencing its size or weight. The
310 monitoring of spleen weight can serve as an indicator of alterations in immune activity or overall immune
311 system health [35, 36].

312 In alignment with this understanding, the administration of CPA to mice in this experiment resulted in a
313 12% reduction in colon length compared with the normal group, along with a 41.6% decrease in spleen
314 weight. Although FAVU treatment did not yield statistically significant changes, it exhibited a clear
315 tendency toward recovery. FAVU low and high treatment groups displayed increased colon length by 5.4%
316 $\pm 0.7\%$ and $3.5\% \pm 0.5\%$, respectively, compared with the CPA group. Regarding spleen weight, the FAVU
317 low and high treatment groups exhibited an $11.1\% \pm 0.8\%$ and $8.3\% \pm 5.7\%$ increase, respectively,
318 compared with the CPA group (Fig. 2D, E). Notably, the marginal differences between the FAVU low and
319 high treatment groups suggest that FAVU has the potential to restore the compromised immune system

320 induced by CPA treatment, with even lower concentrations demonstrating a similar recovery effect as
321 higher doses of FAVU.

322 While the treatment with FAVU did not yield a statistically significant difference in the observed results
323 within this experiment, several factors may account for this outcome. First, the duration of FAVU treatment
324 was comparatively shorter than the conventional timelines associated with general health supplements and
325 dietary regimens [37, 38], which typically extend to 12 months or more as of 2007, particularly in the case
326 of health supplements such as vitamins [38, 39]. Furthermore, in the course of this experiment, antler velvet
327 extract underwent pretreatment before immunosuppression; however, the overall experimental duration
328 was somewhat extended. This raises the prospect that an alternative response might manifest when
329 administering antler velvet extract subsequent to inducing immunosuppression with CPA.

330

331 **Antler velvet extract prevents inflammation in a CPA-induced immunosuppressive mouse model**

332 The relationship between immune suppression and inflammation is intricate and bidirectional. A
333 compromised immune system can lead to inadequate control of inflammatory responses, resulting in
334 chronic infections or prolonged stimuli that trigger inflammation. Conversely, sustained inflammation can
335 detrimentally impact the immune system, potentially causing immune cell exhaustion and contributing to
336 autoimmune disorders [40, 41]. Given our previous examination of CPA toxicity, we anticipated an
337 inflammatory response in mice. Therefore, we assessed inflammatory markers in serum and observed an
338 increase in AST, ALT, and GGT levels in the CPA-treated group (Fig. 3A–C).

339 The interplay between AST, ALT, and GGT is often explored in the context of liver function and health.
340 AST and ALT, primarily found in liver cells, exhibit elevated levels in the bloodstream, indicative of liver
341 damage or inflammation. While ALT is more liver-specific, AST is also present in other tissues. GGT, an
342 enzyme found in the liver and bile ducts, has increased levels associated with liver or biliary diseases.
343 Elevated AST and ALT may suggest hepatocellular damage, whereas heightened GGT levels can indicate

344 issues with the bile ducts [42, 43]. Although statistical significance was not achieved, low and high doses
345 of FAVU appeared effective in preventing liver damage by restoring inflammatory markers to control levels.

346 Furthermore, we observed CPA-induced lipid and glucose metabolic disorders in mice. The CPA-treated
347 group displayed abnormally high levels of total cholesterol alongside reduced glucose levels. The interplay
348 between inflammation, cholesterol, and glucose balance is intricate and interconnected. Chronic
349 inflammation can contribute to dyslipidemia, which is characterized by elevated levels of cholesterol and
350 triglycerides. Inflammatory signals may influence the liver's production of cholesterol and impair the
351 clearance of lipids from the bloodstream. Additionally, inflammation has been associated with insulin
352 resistance, contributing to glucose imbalance and the development of type 2 diabetes. Conversely, elevated
353 cholesterol and abnormal glucose metabolism can themselves trigger inflammatory responses [44-46]. This
354 bidirectional relationship underscores the importance of addressing both inflammation and metabolic
355 imbalances to mitigate the risk of cardiovascular diseases and metabolic disorders. Notably, in our results,
356 FAVU significantly restored total cholesterol and glucose levels, even comparable to the normal control
357 group (Fig. 3D, E). This outcome suggests that antler velvet extract has the potential to prevent immune
358 dysregulation induced by CPA treatment by reducing systemic inflammation and restoring energy
359 metabolism.

360

361 **Antler velvet extract reshapes the gut microbiota**

362 Subsequently, to assess changes in the gut microbiota composition following the administration of CPA
363 and deer antler velvet extract, fecal samples were collected from each experimental group before sacrifice.
364 gDNA was extracted from the fecal samples, and next-generation sequencing was conducted to analyze the
365 microbial community composition. According to previous studies, there is a bidirectional interaction
366 between inflammation and changes in the gut microbiota, where alterations in the gut microbiota can
367 influence immune responses and inflammation, and conversely, inflammatory states can impact the
368 composition of the gut microbiota [47]. Dysbiosis, or an imbalance in the microbial community, has been

369 linked to increased inflammation, potentially contributing to the development or exacerbation of
370 inflammatory conditions. Proinflammatory responses may, in turn, shape the environment in the gut,
371 favoring the growth of certain microbial species while suppressing others. Understanding this intricate
372 interplay between inflammation and gut microbiota composition is crucial for unraveling the mechanisms
373 underlying various health conditions and exploring potential therapeutic interventions targeting the gut
374 microbiome to modulate inflammatory responses [47-49]. From this result, there was no certain difference
375 between groups in alpha diversity, the richness of each bacterial species, whereas beta diversity, which
376 measures the differences in species compositions between the groups, indicated that FAVU treatment
377 proliferates group-specific bacteria (Fig. 4A, B).

378 Therefore, examining the specific compositional changes induced by FAVU treatment compared with
379 the CPA group, the administration of deer antler velvet extract demonstrated a general inclination toward
380 an increase in commensal bacteria. This effect was particularly evident in the notable elevation of specific
381 commensals, including *Lactobacillus* (lactic acid bacteria) [50, 51], *Akkermansia* [52, 53], and
382 *Lachnospiraceae* [51], the established probiotics (Fig. 4C, D). These intriguing findings strongly suggest
383 that the administration of deer antler velvet extract not only contributes to the restoration of gut microbiota
384 composition but also actively fosters the growth of commensal bacteria with well-documented probiotic
385 functions. Consequently, the implications are significant, pointing toward FAVU treatment as a promising
386 avenue to counteract CPA-induced immune dysregulation and inflammation by positively shaping the
387 landscape of commensal bacteria. Moreover, this outcome underscores the potential of antler velvet extract
388 as a potent agent to encourage the proliferation of beneficial commensal bacteria, particularly in the context
389 of diseases.

390

391 **Antler velvet extract enhances NK cell immune response**

392 Finally, in the comprehensive exploration of antler velvet extract's immunomodulatory capabilities, we
393 engaged in a NK cell killing activity assay. This involved the strategic coculturing of YAC-1 lymphoma

394 and Raw264.7 mast cells with NK cells previously exposed to antler velvet extract. Through this coculture
395 study, our objective was to unravel the intricate interactions between NK cells and a commonly utilized
396 target cell line in immunological research. This approach sought to emulate *in vitro* conditions that closely
397 mimic the natural environment of the immune system [54, 55]. The results, as shown in Figure 5, exhibited
398 a statistically significant $33.8\% \pm 3.1\%$ increase in the cytotoxic response of NK cells when they were
399 preincubated with antler velvet extract (Fig. 5A). To delve deeper into the nuances of the antler velvet
400 extract's impact, particularly its potential cytotoxicity or influence on cell culture conditions, we
401 meticulously compared YAC-1 LDH scores to those of a quiescent Raw264.7 cell line [56, 57] (Fig. 5B).
402 Impressively, the findings underscored the dual nature of antler velvet extract's immune-regulatory effects.
403 Antler velvet extract not only augmented the cytotoxic sensitivity of NK cells toward the target cells but
404 also maintained specificity toward the normal cell line; in this case, the macrophages were notably held at
405 baseline levels, revealing the sophisticated and targeted immunomodulatory potential of antler velvet
406 extract.

407

408 **Summary**

409

410 The multifaceted study into the effects of antler velvet extract on *C. elegans* lifespan and associated
411 physiological parameters has provided compelling evidence of its potential therapeutic applications. The
412 meticulous exploration of distinct antler velvet extracts, coupled with an emphasis on the upper regions of
413 antler velvet, revealed a consistent and notable increase in *C. elegans* lifespan. This outcome underscores
414 the host-beneficial nature of antler velvet extracts, emphasizing their safety profile. Beyond lifespan
415 extension, this investigation explores the muscle and cognitive enhancements induced by antler velvet
416 extracts. The results, particularly regarding the protective efficacy of upper antler velvet extracts against
417 motor deficits and cognitive decline, emphasize their promising utility in fostering general well-being and
418 potentially attenuating age-related neurodegenerative disorders.

419 Furthermore, the study ventured into the realm of translational research by examining the potential of
420 antler velvet extract to mitigate the toxicity induced by CPA in a mouse model. The results demonstrated a
421 restorative effect on body weight reduction, immune system-related metrics, and inflammatory markers,
422 suggesting the capacity of antler velvet, particularly the upper region, to counteract the adverse effects of
423 chemotherapy. Additionally, the study provided insights into the modulation of gut microbiota composition,
424 revealing the potential of antler velvet extract, specifically FAVU, to foster the growth of commensal
425 bacteria. The robust immunomodulatory capabilities of antler velvet extract, as evidenced by the enhanced
426 NK cell immune response, further substantiate its potential as a comprehensive therapeutic agent. Overall,
427 this scholarly inquiry offers a nuanced understanding of the diverse benefits of antler velvet extract,
428 encouraging continued research to unravel its full potential for human health and well-being.

429 Nevertheless, it is crucial to acknowledge certain limitations that warrant consideration. First, the study
430 primarily relies on experimental outcomes obtained from *C. elegans* and mouse models. While these models
431 offer valuable insights into physiological responses, their translational relevance to human systems may
432 vary, and caution should be exercised when extrapolating findings directly to clinical scenarios.

433 Moreover, the study predominantly focuses on the upper region of antler velvet extract, specifically
434 FAVU, neglecting potential variations in efficacy across different antler regions. The decision to
435 concentrate on FAVU is based on observed trends, but a more comprehensive exploration of various antler
436 regions could contribute to a more nuanced understanding of the differential effects.

437 Furthermore, the study primarily utilizes *in vitro* and *in vivo* assays, providing mechanistic insights into
438 the immunomodulatory and therapeutic potential of antler velvet extract. However, the complex interplay
439 of factors within the human body, including genetic, environmental, and lifestyle variables, may introduce
440 additional nuances not fully captured in controlled experimental settings.

441

442 **Acknowledgments**

443 This study received support through grants from the National Agricultural Cooperative Federation
444 (NACF) and the Agricultural and Livestock Products Safe Distribution and Consumption Technology
445 Development Program (Project No.320111-1), Korea Institute of Planning and Evaluation for Technology
446 in Food, Agriculture, and Forestry (IPET) and by a National Research Foundation of Korea Grant, funded
447 by the Korean government (MEST) (NRF-2021R1A2C3011051).

448

449

ACCEPTED

450 **References**

- 451
452 1. Kawtikwar PS, Bhagwat DA, Sakarkar DM. Deer antlers-traditional use and future
453 perspectives. 2010.
- 454 2. Wu F, Li H, Jin L, Li X, Ma Y, You J, et al. Deer antler base as a traditional Chinese medicine:
455 a review of its traditional uses, chemistry and pharmacology. *Journal of Ethnopharmacology*.
456 2013;145(2):403-15.
- 457 3. Orassay A, Sadvokassova D, Berdigaliyev A, Sagintayev A, Myrzagali S, Omarova Z, et al.
458 Deer antler extract: Pharmacology, rehabilitation and sports medicine applications.
459 *Pharmacological Research-Modern Chinese Medicine*. 2023:100316.
- 460 4. Widjowati R, Suciati S, Haryadi DM, Chang H-I, Suryawan IN, Tarigan N. The effect of
461 deer antler from East Kalimantan to increase trabecular bone density and calcium levels in
462 serum on osteoporotic mice. *Journal of Basic and Clinical Physiology and Pharmacology*.
463 2021;32(6):1145-50.
- 464 5. Suttie JM, Harris P. Clinical properties of deer velvet. *Positive Health*. 2000;32.
- 465 6. Tseng S-H, Sung C-H, Chen L-G, Lai Y-J, Chang W-S, Sung H-C, et al. Comparison of
466 chemical compositions and osteoprotective effects of different sections of velvet antler.
467 *Journal of Ethnopharmacology*. 2014;151(1):352-60.
- 468 7. Cheng W-J, Yang H-T, Chiang C-C, Lai K-H, Chen Y-L, Shih H-L, et al. Deer velvet antler
469 extracts exert anti-inflammatory and anti-arthritis effects on human rheumatoid arthritis
470 fibroblast-like synoviocytes and distinct mouse arthritis. *The American Journal of Chinese
471 Medicine*. 2022;50(06):1617-43.
- 472 8. Limmatvapirat C, Rodhetbhai P, Somsakraksanti K, Danpongprasert P, Poosub S,
473 Krongrawa W, et al. Chemical constituents, antioxidant activities, and element concentrations
474 of rusa deer velvet antler extracts. *Journal of Chemistry*. 2020;2020:1-8.
- 475 9. Yao B, Zhang M, Leng X, Liu M, Liu Y, Hu Y, et al. Antler extracts stimulate chondrocyte
476 proliferation and possess potent anti-oxidative, anti-inflammatory, and immune-modulatory
477 properties. *In Vitro Cellular & Developmental Biology-Animal*. 2018;54:439-48.

- 478 10. Sun H, Xiao D, Liu W, Li X, Lin Z, Li Y, et al. Well-known polypeptides of deer antler velvet
479 with key actives: modern pharmacological advances. *Naunyn-Schmiedeberg's Archives of*
480 *Pharmacology*. 2023;1-17.
- 481 11. Li C, Li Y, Wang W, Scimeca M, Melino G, Du R, et al. Deer antlers: the fastest growing
482 tissue with least cancer occurrence. *Cell Death & Differentiation*. 2023;1-10.
- 483 12. Landete-Castillejos T, Kierdorf H, Gomez S, Luna S, García AJ, Cappelli J, et al. Antlers-
484 evolution, development, structure, composition, and biomechanics of an outstanding type of
485 bone. *Bone*. 2019;128:115046.
- 486 13. Sui Z, Yuan H, Liang Z, Zhao Q, Wu Q, Xia S, et al. An activity-maintaining sequential
487 protein extraction method for bioactive assay and proteome analysis of velvet antlers. *Talanta*.
488 2013;107:189-94.
- 489 14. Abd Hamid H, Anuar MZAK, Zulkifli FH. Preparation and characterization of deer velvet
490 antler/polyvinyl alcohol (DVA/PVA) scaffold for bone tissue engineering. *Materials Today:*
491 *Proceedings*. 2022;51:1332-7.
- 492 15. Sui Z, Weng Y, Zhao Q, Deng N, Fang F, Zhu X, et al. Ionic liquid-based method for direct
493 proteome characterization of velvet antler cartilage. *Talanta*. 2016;161:541-6.
- 494 16. Jeon B-T, Cheong S-H, Kim D-H, Park J-H, Park P-J, Sung S-H, et al. Effect of antler
495 development stage on the chemical composition of velvet antler in elk (*Cervus elaphus*
496 *canadensis*). *Asian-Australasian Journal of Animal Sciences*. 2011;24(9):1303-13.
- 497 17. Jo SJ, Kim JH, Kim J-W, Choi HO, Lee SH, Kim M-K, et al. Comparative studies on velvet
498 deer antler and ossified deer antler on the contents of bioactive components and on the bone
499 mineral density improving activity for oophorectomized rat. *Natural Product Sciences*.
500 2013;19(4):303-10.
- 501 18. Anderson GL, Cole RD, Williams PL. Assessing behavioral toxicity with *Caenorhabditis*
502 *elegans*. *Environmental Toxicology and Chemistry: An International Journal*.
503 2004;23(5):1235-40.
- 504 19. Deng M, van Meel JC. *Caenorhabditis elegans* as model system for rapid toxicity assessment
505 of pharmaceutical compounds. *Journal of pharmacological and toxicological methods*.
506 2004;50(3):209-14.

- 507 20. Hunt PR. The *C. elegans* model in toxicity testing. *Journal of Applied Toxicology*.
508 2017;37(1):50-9.
- 509 21. Kim JW, Choi J-S, Seol DJ, Choung JJ, Ku SK. Immunomodulatory effects of
510 kuseonwangdago-based mixed herbal formula extracts on a cyclophosphamide-induced
511 immunosuppression mouse model. *Evidence-Based Complementary and Alternative
512 Medicine*. 2018;2018.
- 513 22. Ozolins TR. Cyclophosphamide and the Teratology Society: an awkward marriage. *Birth
514 Defects Research Part B: Developmental and Reproductive Toxicology*. 2010;89(4):289-99.
- 515 23. Robinson LA, Nataraj C, Thomas DW, Cosby JM, Griffiths R, Bautch VL, et al. The
516 chemokine CX3CL1 regulates NK cell activity in vivo. *Cellular immunology*.
517 2003;225(2):122-30.
- 518 24. Tang Y, Yan X, Zhan D, Wen L, Huang R, Zhang Y, et al. Myc Regulates the Development
519 and Anti-Tumor Immunity of Natural Killer Cells. *Blood*. 2018;132:1113.
- 520 25. Choi H, Mun D, Ryu S, Kwak M-j, Kim B-K, Park D-J, et al. Molecular characterization and
521 functionality of rumen-derived extracellular vesicles using a *Caenorhabditis
522 elegans* animal model. *Journal of Animal Science and Technology*. 2023;65(3):652-
523 63.
- 524 26. Yoo J, Lee J, Zhang M, Mun D, Kang M, Yun B, et al. Enhanced γ -aminobutyric acid and
525 sialic acid in fermented deer antler velvet and immune promoting effects. *Journal of Animal
526 Science and Technology*. 2022;64(1):166-82.
- 527 27. Huang X-W, Liu M-L, Wang J-J, Liu Y-X, Lin Z, Rong C-S, et al. Mechanism of Action of
528 Velvet Antler Polypeptide in Improving Mild Cognitive Impairment in Rats. 2023.
- 529 28. Liu X, Yang Q, Li H, Lan X, Kan M, Lin J, et al. The anti-aging effect of velvet antler
530 polypeptide is dependent on modulation of the gut microbiota and regulation of the
531 PPAR α /APOE4 pathway. *Journal of Integrative Neuroscience*. 2021;20(3):573-83.
- 532 29. Xu H, Yang R, Liu Y, Wang J, Lan T, Lin Z, et al. Mechanism of Velvet Antler Peptide in
533 Preventing Mild Cognitive Impairment Based on Non-Targeted Metabolomics. *Journal of
534 Biobased Materials and Bioenergy*. 2022;16(4):581-91.

- 535 30. Kerr R, Lev-Ram V, Baird G, Vincent P, Tsien RY, Schafer WR. Optical imaging of calcium
536 transients in neurons and pharyngeal muscle of *C. elegans*. *Neuron*. 2000;26(3):583-94.
- 537 31. Trojanowski NF, Raizen DM, Fang-Yen C. Pharyngeal pumping in *Caenorhabditis elegans*
538 depends on tonic and phasic signaling from the nervous system. *Scientific reports*.
539 2016;6(1):22940.
- 540 32. Ahn S-I, Cho S, Choi N-J. Effect of dietary probiotics on colon length in an inflammatory
541 bowel disease-induced murine model: A meta-analysis. *Journal of dairy science*.
542 2020;103(2):1807-19.
- 543 33. Cebra JJ. Influences of microbiota on intestinal immune system development. *The American*
544 *journal of clinical nutrition*. 1999;69(5):1046s-51s.
- 545 34. Wells JM, Rossi O, Meijerink M, van Baarlen P. Epithelial crosstalk at the microbiota-
546 mucosal interface. *Proceedings of the national academy of sciences*.
547 2011;108(supplement_1):4607-14.
- 548 35. Artym J. Reconstitution of cyclophosphamide-induced, impaired function of the immune
549 system in animal models. *Postepy Higieny i Medycyny Doswiadczalnej*. 2003;57(1):55-66.
- 550 36. Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide toxicity: characterising and avoiding
551 the problem. *Drugs*. 1991;42:781-95.
- 552 37. Maughan RJ, Burke LM, Dvorak J, Larson-Meyer DE, Peeling P, Phillips SM, et al. IOC
553 consensus statement: dietary supplements and the high-performance athlete. *International*
554 *journal of sport nutrition and exercise metabolism*. 2018;28(2):104-25.
- 555 38. Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-
556 the-counter medication and dietary supplement use among older adults in the United States,
557 2005 vs 2011. *JAMA internal medicine*. 2016;176(4):473-82.
- 558 39. Block G, Jensen CD, Norkus EP, Dalvi TB, Wong LG, McManus JF, et al. Usage patterns,
559 health, and nutritional status of long-term multiple dietary supplement users: a cross-sectional
560 study. *Nutr J*. 2007;6:30.


- 561 40. Brands X, Uhel F, van Vught LA, Wiewel MA, Hoogendijk AJ, Lutter R, et al. Immune
562 suppression is associated with enhanced systemic inflammatory, endothelial and
563 procoagulant responses in critically ill patients. *Plos one*. 2022;17(7):e0271637.
- 564 41. Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor
565 microenvironment. *Carcinogenesis*. 2015;36(10):1085-93.
- 566 42. Bo S, Gambino R, Durazzo M, Guidi S, Tiozzo E, Ghione F, et al. Associations between γ -
567 glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a
568 population-based cohort: a possible implication for oxidative stress. *World journal of*
569 *gastroenterology*. 2005;11(45):7109.
- 570 43. Nebhinani N, Sharma P, Pareek V, Suthar N, Jakhotia S, Gehlot M, et al. Association of
571 inflammatory and liver markers with cardiometabolic risk factors in patients with depression.
572 *Indian Journal of Clinical Biochemistry*. 2019;34:219-24.
- 573 44. Kim M-H, Kim H-N, Choi W-S. The association between subclinical inflammation and
574 abnormal glucose and lipid metabolisms in normal-weight Korean individuals. *Nutrition,*
575 *Metabolism and Cardiovascular Diseases*. 2018;28(11):1106-13.
- 576 45. Petersen KS, Bowen KJ, Tindall AM, Sullivan VK, Johnston EA, Fleming JA, et al. The
577 Effect of Inflammation and Insulin Resistance on Lipid and Lipoprotein Responsiveness to
578 Dietary Intervention. *Current Developments in Nutrition*. 2020;4(11):nzaa160.
- 579 46. Rosenbaum M, Hall KD, Guo J, Ravussin E, Mayer LS, Reitman ML, et al. Glucose and
580 Lipid Homeostasis and Inflammation in Humans Following an Isocaloric Ketogenic Diet.
581 *Obesity (Silver Spring)*. 2019;27(6):971-81.
- 582 47. Zeng M, Inohara N, Nuñez G. Mechanisms of inflammation-driven bacterial dysbiosis in the
583 gut. *Mucosal immunology*. 2017;10(1):18-26.
- 584 48. Kamada N, Seo S-U, Chen GY, Núñez G. Role of the gut microbiota in immunity and
585 inflammatory disease. *Nature Reviews Immunology*. 2013;13(5):321-35.
- 586 49. Lobionda S, Sittipo P, Kwon HY, Lee YK. The role of gut microbiota in intestinal
587 inflammation with respect to diet and extrinsic stressors. *Microorganisms*. 2019;7(8):271.

- 588 50. Nakamoto N, Amiya T, Aoki R, Taniki N, Koda Y, Miyamoto K, et al. Commensal
589 Lactobacillus controls immune tolerance during acute liver injury in mice. *Cell reports*.
590 2017;21(5):1215-26.
- 591 51. Wang J, Lang T, Shen J, Dai J, Tian L, Wang X. Core Gut Bacteria Analysis of Healthy Mice.
592 *Frontiers in Microbiology*. 2019;10.
- 593 52. Bianchimano P, Britton GJ, Wallach DS, Smith EM, Cox LM, Liu S, et al. Mining the
594 microbiota to identify gut commensals modulating neuroinflammation in a mouse model of
595 multiple sclerosis. *Microbiome*. 2022;10(1):1-22.
- 596 53. Ganesh BP, Klopfeisch R, Loh G, Blaut M. Commensal *Akkermansia muciniphila*
597 exacerbates gut inflammation in *Salmonella Typhimurium*-infected gnotobiotic mice. *PloS*
598 *one*. 2013;8(9):e74963.
- 599 54. Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. *Journal*
600 *of leukocyte biology*. 2019;105(6):1319-29.
- 601 55. Sheppard S, Santosa EK, Lau CM, Violante S, Giovanelli P, Kim H, et al. Lactate
602 dehydrogenase A-dependent aerobic glycolysis promotes natural killer cell anti-viral and
603 anti-tumor function. *Cell reports*. 2021;35(9).
- 604 56. Phukan K, Devi R, Chowdhury D. Insights into anti-inflammatory activity and internalization
605 pathway of onion peel-derived gold nano bioconjugates in RAW 264.7 macrophages. *ACS*
606 *omega*. 2022;7(9):7606-15.
- 607 57. Capiralla H, Vingtdeux V, Venkatesh J, Dreses-Werringloer U, Zhao H, Davies P, et al.
608 Identification of potent small-molecule inhibitors of STAT 3 with anti-inflammatory
609 properties in RAW 264.7 macrophages. *The FEBS journal*. 2012;279(20):3791-9.

610

611

Figure legends




613

614 Fig. 1 Advantageous impacts of antler velvet extracts on age-induced degenerations in the

615 *Caenorhabditis elegans* model.

616 The antiaging effects of antler velvet extracts were validated through (A–F) *C. elegans* lifespan assay. The
617 locomotion changes were assessed through (G) thrashing and (H) pharyngeal pumping rate assays.
618 Cognitive ability and brain functionality were assessed indirectly through the chemotaxis assay using (I)
619 the attractant and (J) the repellent substances. Furthermore, the chemical and mechanical neuronal function
620 protective effects of antler velvet extract were evaluated using (K–N) transgenic neurodegenerative *C.*
621 *elegans* model, CL4176. All values are expressed as mean \pm SD; significant differences were determined
622 using Student's t-test and ANOVA at $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, and $****p < 0.0001$. OP50, *E.*
623 *coli* OP50; LGG, *L. rhamnosus* GG. FAV, fresh antler velvet extract; FFA, fermented freeze-dried antler
624 velvet extract; DAV, dried antler velvet extract; CFA, naturally shed antler extract from an aged deer. U,
625 upper region of the antler velvet; M, middle region of the antler velvet; B, base region of the antler velvet.
626



627

628


629 **Fig. 2 Physiological prevention effect of the fresh antler velvet extract on the CPA-induced**
 630 **immunosuppressive mouse model.** (A) The experimental scheme. The physiological recovery effect of
 631 the FAVU on the CPA-induced immunosuppressive mouse model was assessed through (B) body weight
 632 change, (C) daily feed intake, (D) colon length, and (E) spleen weight. All values are expressed as mean \pm

633 SD; significant differences were determined using Student's t-test and ANOVA at $*p < 0.05$ and $***p <$
634 0.001 . CONT, normal group; CPA, PBS + CPA (100 mg/kg); FAVU100, upper region fresh antler velvet
635 extract (100 mg/kg) CPA (100 mg/kg); FAVU300, upper region fresh antler velvet extract (300 mg/kg)
636 CPA (100 mg/kg).

637

638

ACCEPTED




640

641 **Fig. 3 Immunomodulatory effect of the fresh antler velvet extract on the CPA-induced**
 642 **immunosuppressive mouse model.**

643 Examining the immunomodulatory effect of fresh antler velvet extract involved the evaluation of systemic
 644 inflammatory markers, including (A) AST, (B) ALT, and (C) GGT, from the serum. The analysis extended
 645 to assessing the metabolic modulatory effect by examining serum levels of (D) total cholesterol and (E)
 646 glucose. All values are expressed as mean \pm SD; significant differences were determined using Student's t-
 647 test and ANOVA at * $p < 0.05$ and *** $p < 0.001$. CONT, normal group; CPA, PBS + CPA (100 mg/kg);
 648 FAVU100, upper region fresh antler velvet extract (100 mg/kg) CPA (100 mg/kg); FAVU300, upper region
 649 fresh antler velvet extract (300 mg/kg) CPA (100 mg/kg).

650

651



652

653 **Fig. 4 Antler velvet extract reshapes the gut microbiota.** A metagenomic study was conducted to explore

654 the microbiome's relative abundance. (A) The alpha diversity of the microbiome in fecal samples from each

655 group is represented by the Chao and Shannon index values. The data are presented as means \pm SEMs ($n =$

656 4 per group), and significant differences were assessed using one-way ANOVA. (B) PCoA plots were

657 generated based on weighted and unweighted UniFrac distances of the fecal microbiome from each group,


658 revealing distinct clusterings. The metagenomic analysis showed variations in the compositions of bacterial

659 genera at the (C) phylum and family levels for each group. (D) Heatmap provides intuitive visualization of
660 microbiome. Each colored cell on the map corresponds to relative abundances.

661

662

ACCEPTED



663

664 **Fig. 5 Antler velvet extract boosts the cytotoxic activity of Natural killer (NK) cells.** To assess this

665 activity, an LDH assay was conducted by coculturing NK cells with (A) YAC-1 lymphoma cells and (B)

666 quiescent Raw264.7 mast cells. To maintain the baseline activity of Raw264.7 cells, no stimuli were

667 introduced during the culture. All values are expressed as mean \pm SD; significant differences were

668 determined using Student's t-test and ANOVA at *** $p < 0.001$ and **** $p < 0.0001$.

669